covid_cell_1_20’s weekly COVID-19 news round-up

pharmafile | May 19, 2021 | News story | Research and Development  

The past week has seen lots of positive COVID-19 vaccine news; the Pfizer-BioNTech vaccine can be refrigerated much longer than initially thought, a study has shown that 96% people develop antibodies after just one COVID-19 jab, and a delayed Pfizer vaccine dose by 12 weeks can give 3.5 times more immunity.

 1. Pfizer-BioNTech vaccine can be kept in fridge longer than previously thought – Published 18/05/2021

The EMA has extended the recommended approved storage period for an unopened thawed vial of the Pfizer-BioNTech vaccine from five days to one month.

 2. Major UK study finds 96% people develop antibodies after one COVID-19 jab – Published 18/05/21

 More than 96% of people develop antibodies after just one COVID-19 jab of either AstraZeneca or Pfizer, and almost 100% do after both doses, a UK study has found.

 3. Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows – Published – 14/05/21

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed 12 weeks apart, a Birmingham University study has shown.

 4. India approves Covaxin clinical trials for children aged 2-18 years old – Published 13/05/21

The Drugs Controller General of India (DCGI) has cleared Bharat Biotech’s Covaxin trials on children from 2-18 years old.

 5. Sanofi and GSK’s COVID-19 vaccine shows promising results in Phase II trialPublished 17/05/21

The adjuvanted recombinant COVID-19 vaccine produced by Sanofi and GSK has demonstrated strong immune responses across all adult age groups in its Phase II trial.

Related Content

No items found

Latest content